Amgen’s (NASDAQ: AMGN) top and bottom line in the first quarter of 2020 beat analysts’ estimates. The biotech firm’s adjusted earnings per share surged 17% to $4.17, driven by increased revenues and fewer weighted-average shares outstanding. Revenue rose 11% annually to $6.2 billion. AMGN stock was trading up about 1% during the extended-hours.
GAAP earnings per share decreased 3% to $3.07 in the first quarter. Product sales increased 12% globally, driven by volume growth across a number of Amgen’s newer products.
Amgen reaffirmed its 2020 revenue guidance of $25.0 billion to-$25.6 billion. GAAP EPS guidance was revised to a range of $10.65 to $11.45 and the company maintained the non-GAAP EPS outlook of $14.85-$15.60.
Amgen announced that Otezla, an oral treatment approved in more than 50 countries for inflammatory diseases such as psoriasis and psoriatic arthritis, will be investigated as a potential immunomodulatory treatment in adult patients with COVID-19 in upcoming platform trials.
After starting the week on a positive note, major stock indexes witnessed volatility and slipped mid-week. Meanwhile, the S&P 500 index regained a part of the lost momentum and closed
The TJX Companies Inc. (NYSE: TJX) saw sales slightly drop during the third quarter of 2021 while earnings benefited from lower tax rates. Open-only comp store sales were down 5%
Value investors have long viewed the fintech industry as a gold mine of opportunities in the years to come, with payment processing services carrying a fair share of interest. Those